Research ArticleCancer

Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines

Sci. Signal.  24 Sep 2013:
Vol. 6, Issue 294, pp. ra84
DOI: 10.1126/scisignal.2004379

You are currently viewing the editor's summary.

View Full Text
As a service to the community, AAAS/Science has made this article free with registration.

Hybrid Biomarkers

Changes in genes only tell part of the story in cancer. Cancer cells also exhibit altered signaling networks and can rewire their signaling pathways in response to either endogenous stimuli or drug therapy. Niepel et al. combined information about breast cancer clinical subtype, genetic status, receptor abundance, and signaling pathway activity to create hybrid biomarkers that predicted the effectiveness of various targeted breast cancer therapies. This approach may prove a better way to customize treatments for cancer patients because it accounts for heterogeneity in tumors with similar genetic alterations and because the multitude of genetic changes observed in cancer appear to result in a smaller set of dysregulated signaling states.